AstraZeneca Pharma India Limited (BOM:506820)
8,063.60
+37.65 (0.47%)
At close: Jul 20, 2026
AstraZeneca Pharma India Employees
AstraZeneca Pharma India had 760 employees as of March 31, 2026. The number of employees decreased by 42 or -5.24% compared to the previous year.
Employees
760
Change (1Y)
-42
Growth (1Y)
-5.24%
Revenue / Employee
37.93M INR
Profits / Employee
3.13M INR
Market Cap
201.59B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 760 | -42 | -5.24% |
| Mar 31, 2025 | 802 | -138 | -14.68% |
| Mar 31, 2024 | 940 | -7 | -0.74% |
| Mar 31, 2023 | 947 | -236 | -19.95% |
| Mar 31, 2022 | 1,183 | -100 | -7.79% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| FDC Limited | 6,857 |
| J. B. Chemicals & Pharmaceuticals | 5,602 |
| Jubilant Pharmova | 5,547 |
| CORONA Remedies | 5,153 |
| Granules India | 4,066 |
| Caplin Point Laboratories | 3,966 |
| GlaxoSmithKline Pharmaceuticals | 3,103 |
| Procter & Gamble Health | 1,326 |
AstraZeneca Pharma India News
- 14 days ago - AstraZeneca Pharma India appoints Mihir Parikh and Amay Ashok Pandey to key director roles - Business Upturn
- 4 weeks ago - AstraZeneca Pharma India appoints Praveen K Mittal as Director - Corporate Affairs - Business Upturn
- 5 weeks ago - AstraZeneca Pharma India announces resignation of senior management personnel - Business Upturn
- 5 weeks ago - AstraZeneca gets CDSCO approval to sell Enhertu in India for first-line HER2-positive breast cancer treatment - Business Upturn
- 7 weeks ago - Why are AstraZeneca Pharma shares down over 4% today? Explained - Business Upturn
- 7 weeks ago - AstraZeneca Pharma India Quarterly report: Q4 2026 - Filings
- 7 weeks ago - AstraZeneca Pharma India Annual report: Q4 2026 - Filings
- 7 weeks ago - AstraZeneca Pharma India reports 33% revenue growth for FY 2025-26 - Business Upturn